Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival

Success of immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) has invigorated their use in the neoadjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the early immune responses to therapy remain poorly understood. Through an integrated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCI Insight
Hauptverfasser: Markowitz, Geoffrey J., Havel, Lauren S., Crowley, Michael J.P., Ban, Yi, Lee, Sharrell B., Thalappillil, Jennifer S., Narula, Navneet, Bhinder, Bhavneet, Elemento, Olivier, Wong, Stephen T.C., Gao, Dingcheng, Altorki, Nasser K., Mittal, Vivek
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2018
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6101707/
https://ncbi.nlm.nih.gov/pubmed/29997286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96836
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge